Cardiac toxicity from osimertinib in cancer patients and ways to prevent it
Official title: Investigating Cardiotoxicity of Osimertinib: Mechanisms and Therapeutic Interventions
Funded at University of Michigan at Ann Arbor · NIH-11337938 · Data updated 2026-11-12
This grant studies why the cancer drug osimertinib can harm the heart and tests strategies to stop this damage, with the goal of helping patients stay on life-saving cancer therapy safely.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | June 1, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $444,775 |
| NIH project number | 1R01HL185027-01 |
| Project ID | NIH-11337938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with EGFR T790M-positive non-small cell lung cancer receiving osimertinib or at risk for cardiotoxicity.
✕Less likely to help
Patients unlikely to benefit include those not treated with osimertinib or without cardiac risk factors related to this drug.
What this research studies
Osimertinib is a crucial cancer drug, but some patients develop heart problems like reduced heart function or arrhythmias. The project uses mouse models to explore how mitochondrial oxidative stress and NOX4 contribute to this toxicity and tests potential preventive treatments that protect the heart without reducing anticancer effects. The team plans to translate these findings toward strategies that can be used alongside cancer care to reduce interruptions in therapy. By understanding the mechanism, the research aims to identify actionable interventions for patients who need osimertinib. The work is conducted at the University of Michigan with the goal of informing safer use of this therapy in NSCLC.
Why it matters
Potential benefit: If successful, patients on osimertinib could experience fewer cardiac side effects and stay on effective cancer treatment longer.
How similar studies have gone: Preclinical work in mouse models has shown a link between mitochondrial oxidative stress and cardiotoxicity, supporting further exploration.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Singh, Anand Prakash — University of Michigan at Ann Arbor
- Study coordinator: Singh, Anand Prakash
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.